<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264446</url>
  </required_header>
  <id_info>
    <org_study_id>Adherex Protocol # AHX-03-101</org_study_id>
    <nct_id>NCT00264446</nct_id>
  </id_info>
  <brief_title>A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection</brief_title>
  <official_title>Phase 1 Study of the Evaluation of Dihydropyrimidine Dehydrogenase (DPD), Uridine Phosphorylase (UP), Orotate Phosphoribosyl Transferase (OPRT), and Thymidine Phosphorylase (TP) Activity in Tissue Resected From Subjects Undergoing Planned Resection of Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection, Following Administration of Oral ADH300004 (Adherex Protocol Number AHX-03-101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adherex Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adherex Technologies, Inc.</source>
  <brief_summary>
    <textblock>
      5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly&#xD;
      inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This&#xD;
      study will examine the kinetics of inhibition and recovery of the metabolic pathways for&#xD;
      fluoropyrimidines in subjects who receive a single oral dose of ADH300004, and may allow&#xD;
      optimization of oral 5 FU dosing to subjects in future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADH300004</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  &gt; or = 19 years of age&#xD;
&#xD;
          -  Patients with histologically confirmed:&#xD;
&#xD;
               -  primary or metastatic (known or suspected) colorectal carcinoma requiring planned&#xD;
                  surgical resection with hepatic biopsy and systemic chemotherapy , or&#xD;
&#xD;
               -  primary or metastatic neoplastic disease within the liver from any origin&#xD;
                  requiring planned surgical resection and systemic chemotherapy&#xD;
&#xD;
          -  Adequate performance status and organ function, as evidenced by hematological and&#xD;
             biochemical blood testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of known or suspected metastatic disease in the liver&#xD;
&#xD;
          -  Known DPD deficiency&#xD;
&#xD;
          -  Severe infection&#xD;
&#xD;
          -  Inability to take oral medication&#xD;
&#xD;
          -  The need for treatment with any fluoropyrimidine within 8 weeks of any ADH300004 dose&#xD;
&#xD;
          -  Stroke, major surgery, or other major tissue injury within 30 days before study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Heslin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB - Division of Surgery</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.adherex.com</url>
    <description>Adherex Technologies Inc. Corporate Homepage</description>
  </link>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>December 12, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <last_update_submitted>August 3, 2007</last_update_submitted>
  <last_update_submitted_qc>August 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2007</last_update_posted>
  <keyword>Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents;</keyword>
  <keyword>Dihydrouracil dehydrogenase (NADP); Colorectal Carcinoma; Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eniluracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

